» Scarica il Programma

ROMA, 11 th – 12th December 2025
presso Hotel Donna Camilla Savelli

RESPONSABILI SCIENTIFICI
Prof.ssa Laura De Marinis
Coordinatore Scientifico del Master Universitario di II Livello in diagnosi e terapia delle patologie
ipotalamo-ipofisarie – Università Cattolica del Sacro Cuore – Roma
Dott. Antonio Bianchi
Dirigente medico I livello U.O.S. di Patologie Ipotalamo-ipofisarie – Fondazione Policlinico Universitario
A. Gemelli – IRCCS Roma

SEGRETERIA SCIENTIFICA
Dott.ssa Sabrina Chiloiro, Dott.ssa Antonella Giampietro
UOS Patologia Ipotalamo Ipofisaria, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma

Dott. Domenico Milardi
U.O.C. Medicina Interna, Endocrinologia, Diabetologia Fondazione Policlinico Universitario A.Gemelli IRCCS, Roma

SEDE DELL’EVENTO
Hotel Donna Camilla Savelli
Via Garibaldi, 27 – 00153 Roma – Tel. 06 588 861

PROVIDER ECM E SEGRETERIA ORGANIZZATIVA

Provider Standard accreditato presso la Commissione Nazionale ECM – ID 680

DOTCOM SRL
Via Flaminia, 54 | 00196 Roma
Tel. 06 406 1370 | Fax 06 324 2600
E-Mail: info@dotcomeventi.com
Sito web: www.dotcomeventi.com

ECM 680 – 464787
Assegnati n. 11 crediti formativi ECM

L’evento è accreditato per n° 100 partecipanti per le seguenti figure professionali:
• Medico – Chirurgo: Anatomia Patologica, Chirurgia Generale, Endocrinologia, Gastroenterologia,
Genetica Medica, Malattie Metaboliche e Diabetologia, Medicina Interna, Medicina Nucleare, Neurochirurgia,
Neuroradiologia, Oftalmologia, Otorinolaringoiatria, Patologia Clinica (Laboratorio
di Analisi Chimico- Cliniche e Microbiologia), Radiodiagnostica, Radioterapia.
• Infermiere

PRE-ISCRIZIONE
La pre-iscrizione potrà essere effettuata online collegandosi al sito www.dotcomeventi.com nella
sezione “EVENTI & CONGRESSI IN CORSO”. L’accesso in aula è riservato ai primi 100 partecipanti.
Si ricorda che l’attestazione dei crediti formativi ECM è subordinata alla partecipazione del 90%
della durata dei lavori, alla compilazione della scheda di valutazione dell’evento e al superamento
della prova di apprendimento (questionario, almeno 75% risposte esatte).

OBIETTIVO FORMATIVO
Documentazione clinica. Percorsi clinico-assistenziali diagnostici e riabilitativi, profili di assistenza
– profili di cura

RAZIONALE SCIENTIFICO
Pituitary adenomas/PitNET represents a complex disease, with a wide spectrum of
clinical manifestations, from small benign lesions to aggressive PitNET, according to
the ability of secreting different hormones or pro-hormones orof invading the neighbouring
anatomical structures and to treatment resistance.
Macroadenomas can cause mass effect, consisting of visualfield defects, headache or
hypopituitarism. People with hypopituitarism due to pituitary adenomas have an approximately
2-fold increase in all-cause mortality compared with the general population
Some syndromes of pituitary hormone excess are also associated with excess
all-cause mortality. Acromegaly was associated with a 2-fold increase in all-cause
mortality rate in studies published before 2008, but not in more recently published
studies or in the subgroups of patients who achieved biochemical control of the disease.
Cushing disease has been associated with a 3-fold increase in all-cause mortality
rate. Aggressive PitNETs (APTs) are a small subset, around 10 % of all PitNETs,
defined as tumours which are radiologically invasive with unusually rapid tumour
growth or clinically relevant tumour growth despite optimal standard therapies Pituitary
carcinomas (PCs) specifically denote APTs that have metastasised (craniospinal
or systemic) and comprise up to 0.4 % of all PitNETs.

Current guidelines for the management of APTs and PCs recommend treatment with
surgery, radiotherapy and temozolomide; however by definition these tumours progress
despite these therapies and treatment options beyond current recommendations
are experimental. In this field, precision medicine management is a rapidly expanding
area that enables delivery of molecular based personalised therapies, and
this approach may improve outcomes for patients with PitNET.In the recent years, a
wide number of research investigated the genetic, molecular and biological features
of PitNETs, in order to predict the clinical behaviour of these neoplasia and to personalize
the treatments.

The current event has the aim of updating participants on the latest biological, genetic
and clinical acquisitions on PitNET and on their impact in the management of
PitNET affected patients according to the new knowledge, that requires a close clinical
collaboration between neuroendocrinologist, ophphtalmologist, pathologists,
neurosurgeons, radiotherapist and nuclear medicine physician.
The meeting is part of the teaching activities of the Master Degree in Diagnosis and
Treatment of pituitary disease – Faculty of Medicine, Università’ Cattolica del Sacro
Cuore, Rome.

Con la sponsorizzazione non condizionante di